Takeda Inflammatory Bowel Drug Wins EU Regulatory Backing
This article is for subscribers only.
A European Medicines Agency committee backed Takeda Pharmaceutical Co.’s treatment for ulcerative colitis and Crohn’s disease.
The Committee for Medicinal Products for Human Use recommended granting marketing authorization for Entyvio for adults who didn’t respond to or couldn’t tolerate other treatments, the London-based regulator said today in a statement. The European Commission usually follows the panel’s advice.